ArticleThoracic cancer2018

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.

Te-Chun Hsia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.